	US 12,227,561 B2
	Connexin 43 antibodies and use thereof
Yanfeng Zhang, Princeton, NJ (US)
Assigned to ALAMAB THERAPEUTICS, INC., Princeton, NJ (US)
Appl. No. 17/045,001
Filed by AlaMab Therapeutics, Inc., Princeton, NJ (US)
PCT Filed Apr. 2, 2019, PCT No. PCT/US2019/025363 § 371(c)(1), (2) Date Oct. 2, 2020, PCT Pub. No. WO2019/195273, PCT Pub. Date Oct. 10, 2019.
Claims priority of provisional application 62/651,668, filed on Apr. 2, 2018.
Prior Publication US 2021/0163581 A1, Jun. 3, 2021
Int. Cl. C07K 16/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 39/39533 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01)]

11 Claims

1. An anti-Cx43 antibody, or antigen binding fragment thereof, comprising: a first, second and third heavy chain complementarity determining region (CDR) sequence having the amino acid sequence of SEQ ID NOs: 1, 2, and 3, respectively; and a first, second and third light chain CDR sequence having the amino acid sequence of SEQ ID NOs: 4, 5, and 6, respectively;

wherein the antibody or fragment thereof comprises a heavy chain variable domain having the amino acid sequence having at least 95% sequence identity to SEQ ID NO: 7, and a light chain variable domain having the amino acid sequence having at least 95% sequence identity to SEQ ID NO: 8.